person · Reporting owner

BERNS PAUL L

Disclosed activity across 8 companies

Tapewire entity: 20890
SEC CIK: 0001202769

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kardigan, Inc.KARD · Entity 4569	Director · 10% owner	June 22, 2026	June 24, 2026
Lyell Immunopharma, Inc.LYEL · Entity 5757	10% owner	March 06, 2026	March 09, 2026
Neumora Therapeutics, Inc.NMRA · Entity 6115	Director · See Remarks	August 20, 2026	August 21, 2026
Unity Biotechnology, Inc.UBX · Entity 77428	Director	June 21, 2024	June 21, 2024
Yarrow Bioscience, Inc.MNLO · Entity 6871	Director	June 25, 2019	August 09, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kardigan, Inc.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy ARCH Venture Fund XIII, L.P.	15,042,035	Reported balance After 2026-06-22 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-06-22 · Purchase · Acquired 1,250,000 · Balance 15,042,035 F1: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	Direct	20,706	Reported balance Holding disclosure · report date 2026-06-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 20,706 F2: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F2: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Lyell Immunopharma, Inc.

Report date March 06, 2026 · Filed March 09, 2026

Jointly reported with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BYBEE CLINTON

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,426,528	Reported balance After 2026-03-06 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-03-06 · Purchase · Acquired 488,090 · Balance 1,426,528 F1: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	910,317	Reported balance Holding disclosure · report date 2026-03-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 910,317 F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee footnote	910,317	Reported balance Holding disclosure · report date 2026-03-06 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 910,317 F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F2: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

F3: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

Neumora Therapeutics, Inc.

Report date August 20, 2026 · Filed August 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-08-20	Direct	500,000	Reported balance After 2026-08-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-20 · Grant · Acquired 500,000 · Balance 500,000 F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Unity Biotechnology, Inc.

Report date June 21, 2024 · Filed June 21, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2034-06-20	Direct	10,000	Reported balance After 2024-06-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-21 · Grant · Acquired 10,000 · Balance 10,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.

Yarrow Bioscience, Inc.

Report date June 25, 2019 · Filed August 09, 2019 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.02 · Expires 2029-06-25	Direct	65,780	Reported balance After 2019-06-25 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2019-06-25 · Grant · Acquired 22,500 · Balance 65,780 F1: The shares subject to the option will fully vest on the one year anniversary of the transaction date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will fully vest on the one year anniversary of the transaction date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EQRx, Inc.

Report date November 09, 2023 · Filed November 09, 2023

Section 16 reporting ended · disclosed 2023-11-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-09 transaction · row 1 1 source row Row 1 · 2023-11-09 · Disposition to issuer · Disposed 627,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2032-09-30	Direct	Reported balance After 2023-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-09 · Disposition to issuer · Disposed 101,010 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	Direct	Reported balance After 2023-11-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-11-09 · Disposition to issuer · Disposed 86,344 · Balance 0 F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 86,344 shares of Issuer common stock (the "Earn-out Shares"), (i) 60,441 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,903 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.

F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).

F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 86,344 shares of Issuer common stock (the "Earn-out Shares"), (i) 60,441 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,903 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Jazz Pharmaceuticals plc

Report date August 05, 2021 · Filed August 09, 2021

Section 16 reporting ended · disclosed 2021-08-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	8,290	Reported balance After 2021-08-05 transaction · row 1 1 source row Row 1 · 2021-08-05 · Sale · Disposed 1,450 · Balance 8,290 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Metsera, Inc.

Report date November 13, 2025 · Filed November 13, 2025

Section 16 reporting ended · disclosed 2025-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-11-13 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2025-11-13 · Disposition to issuer · Disposed 4,031 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-11-13 transaction · row 4 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 4 · 2025-11-13 · Disposition to issuer · Disposed 957,559 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2025-11-13 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-11-13 · Disposition to issuer · Disposed 7,523,682 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F8: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2025-11-13 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2025-11-13 · Disposition to issuer · Disposed 8,313,680 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F8: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	4,031	Reported balance After 2025-11-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-11-13 · Grant · Acquired 4,031 · Balance 4,031 F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2035-05-19	Direct	0	Reported balance After 2025-11-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-11-13 · Disposition to issuer · Disposed 24,188 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F6: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.18 · Expires 2034-11-11	Direct	0	Reported balance After 2025-11-13 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-11-13 · Disposition to issuer · Disposed 223,430 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F7: This option provided for vesting in 36 substantially equal monthly installments from November 12, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus

F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").

F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,

F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.

F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. There is no vesting applicable to the cash payment and the CVRs.

F6: This option provided for vesting in 12 substantially equal monthly installments from May 20, 2025.

F7: This option provided for vesting in 36 substantially equal monthly installments from November 12, 2024.

F8: Represents shares of Common Stock held directly by ARCH Venture Fund XIII, L.P.("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 24, 2022 Filed Jun 27, 2022 17:43 UTC	Unity Biotechnology, Inc. UBX · Entity 77428	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $0.59	$0.00	Disclosure SEC source: 0000899243-22-024215 · doc4.xml · derivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2022 or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantEarn-out Shares · Derivative	85,891	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-049123 · doc4.xml · derivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,891 Underlying: Common Stock · 85,891 shares Expires 2024-12-17 F2 · derivative.exercise_price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 85,891 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 60,124 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,767 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F2 · kind: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 85,891 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 60,124 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,767 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F2 · price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 85,891 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 60,124 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,767 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F2 · derivative.exercise_date: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 85,891 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 60,124 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 25,767 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantCommon Stock	627,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-049123 · doc4.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,000 F1 · kind: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. F1 · price: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. Read SEC document
August 05, 2021 Filed Aug 9, 2021 22:37 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,450	$154.00	$223,300.00	Disclosure SEC source: 0001765581-21-000096 · edgardoc.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,290 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
June 24, 2021 Filed Jun 28, 2021 17:15 UTC	Unity Biotechnology, Inc. UBX · Entity 77428	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $4.18	$0.00	Disclosure SEC source: 0000899243-21-026224 · doc4.xml · derivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-23 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2021 or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document
November 04, 2020 Filed Nov 5, 2020 00:33 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3,825	$150.90	$577,185.62	Disclosure SEC source: 0001765581-20-000107 · edgardoc.xml · nonDerivative · entry 4 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,740 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $150.515 to $151.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
November 04, 2020 Filed Nov 5, 2020 00:33 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	400	$149.28	$59,711.00	Disclosure SEC source: 0001765581-20-000107 · edgardoc.xml · nonDerivative · entry 3 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,565 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.04 to $149.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
November 04, 2020 Filed Nov 5, 2020 00:33 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	466	$147.44	$68,707.04	Disclosure SEC source: 0001765581-20-000107 · edgardoc.xml · nonDerivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,965 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
November 02, 2020 Filed Nov 5, 2020 00:33 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionPhantom Stock · Derivative	4,691	Not disclosed	Not disclosed	Disclosure SEC source: 0001765581-20-000107 · edgardoc.xml · derivative · entry 5 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,691 shares Expires 2020-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 2, 2020, the Reporting Person's 4,691 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares. F1 · price: On November 2, 2020, the Reporting Person's 4,691 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares. Read SEC document
November 02, 2020 Filed Nov 5, 2020 00:33 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	4,691	Not disclosed	Not disclosed	Disclosure SEC source: 0001765581-20-000107 · edgardoc.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 2, 2020, the Reporting Person's 4,691 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares. Read SEC document
August 07, 2020 Filed Aug 10, 2020 20:40 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	931	$125.87	$117,185.44	Disclosure SEC source: 0001765581-20-000067 · edgardoc.xml · nonDerivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,740 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:40 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	6,765	$0.00 Strike: $127.07	$0.00	Disclosure SEC source: 0001765581-20-000067 · edgardoc.xml · derivative · entry 3 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Underlying: Ordinary Shares · 6,765 shares Expires 2030-08-05 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021. Read SEC document
August 06, 2020 Filed Aug 10, 2020 20:40 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	2,705	$0.00	$0.00	Disclosure SEC source: 0001765581-20-000067 · edgardoc.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,671 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021. Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:29 UTC	Unity Biotechnology, Inc. UBX · Entity 77428	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $9.14	$0.00	Disclosure SEC source: 0000899243-20-017396 · doc4.xml · derivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 18, 2020 or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document
August 09, 2019 Filed Aug 12, 2019 21:07 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	726	$135.65	$98,481.10	Disclosure SEC source: 0001765581-19-000060 · edgardoc.xml · nonDerivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,966 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.4565 to $135.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document
August 08, 2019 Filed Aug 12, 2019 21:07 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	4,805	$0.00 Strike: $137.12	$0.00	Disclosure SEC source: 0001765581-19-000060 · edgardoc.xml · derivative · entry 3 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Ordinary Shares · 4,805 shares Expires 2029-08-07 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. Read SEC document
August 08, 2019 Filed Aug 12, 2019 21:07 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,920	$0.00	$0.00	Disclosure SEC source: 0001765581-19-000060 · edgardoc.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,692 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020. Read SEC document
June 25, 2019 Filed Jun 27, 2019 20:18 UTC	Yarrow Bioscience, Inc. MNLO · Entity 6871	GrantStock Option · Derivative	22,500	$0.00 Strike: $6.02	$0.00	Disclosure SEC source: 0000899243-19-018361 · doc4.xml · derivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,780 Underlying: Common Stock · 22,500 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the one year anniversary of the transaction date. Read SEC document
June 25, 2019 Filed Aug 9, 2019 01:18 UTC Amendment	Yarrow Bioscience, Inc. MNLO · Entity 6871	GrantStock Option · Derivative	22,500	$0.00 Strike: $6.02	$0.00	Disclosure SEC source: 0000899243-19-021421 · doc4a.xml · derivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,780 Underlying: Common Stock · 22,500 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the one year anniversary of the transaction date. Read SEC document
June 20, 2019 Filed Jun 24, 2019 16:10 UTC	Unity Biotechnology, Inc. UBX · Entity 77428	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $9.00	$0.00	Disclosure SEC source: 0001567619-19-013863 · doc1.xml · derivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 20, 2019 or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Non-Employee Director until such vesting date. Read SEC document
August 10, 2018 Filed Aug 13, 2018 22:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	660	$176.61	$116,563.19	Disclosure SEC source: 0001232524-18-000152 · edgardoc.xml · nonDerivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,772 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.61 to $177.20. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 09, 2018 Filed Aug 13, 2018 22:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,735	$0.00 Strike: $177.73	$0.00	Disclosure SEC source: 0001232524-18-000152 · edgardoc.xml · derivative · entry 3 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,735 Underlying: Ordinary Shares · 3,735 shares Expires 2028-08-08 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. Read SEC document
August 09, 2018 Filed Aug 13, 2018 22:52 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,495	$0.00	$0.00	Disclosure SEC source: 0001232524-18-000152 · edgardoc.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,432 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019. Read SEC document
May 07, 2018 Filed May 7, 2018 18:23 UTC	Unity Biotechnology, Inc. UBX · Entity 77428	ConversionSeries C Preferred Stock · Derivative	3,261	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-18-022048 · doc1.xml · derivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,261 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document
May 07, 2018 Filed May 7, 2018 18:23 UTC	Unity Biotechnology, Inc. UBX · Entity 77428	ConversionCommon Stock	3,261	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-18-022048 · doc1.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering. Read SEC document
August 11, 2017 Filed Aug 14, 2017 21:15 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	3	$144.13	$432.39	Disclosure SEC source: 0001232524-17-000136 · edgardoc.xml · nonDerivative · entry 3 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,937 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 11, 2017 Filed Aug 14, 2017 21:15 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	659	$142.36	$93,815.24	Disclosure SEC source: 0001232524-17-000136 · edgardoc.xml · nonDerivative · entry 2 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,940 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:15 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantNon-Qualified Stock Option (right to buy) · Derivative	3,415	$0.00 Strike: $143.66	$0.00	Disclosure SEC source: 0001232524-17-000136 · edgardoc.xml · derivative · entry 4 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 Underlying: Ordinary Shares · 3,415 shares Expires 2027-08-09 F3 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:15 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	1,365	$0.00	$0.00	Disclosure SEC source: 0001232524-17-000136 · edgardoc.xml · nonDerivative · entry 1 BERNS PAUL L · CIK 0001202769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,599 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. F1 · shares: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.